Affiliation:
1. Department of Spleen and Stomach Diseases, Jinhua Hospital of Traditional Chinese Medicine, Jinhua, China
2. Department of Quality Control Section, Jinhua Hospital of Traditional Chinese Medicine, Jinhua, China.
Abstract
Background:
Qi deficiency in the spleen and stomach is considered to be the fundamental pathogenesis of chronic atrophic gastritis (CAG) in Traditional Chinese medicine. Spleen strengthening and Qi replenishment are the basic treatment principles. Sijunzi Decoction serves as the fundamental remedy for spleen notification and Qi replenishment.
Methods:
The Cochrane Library, China National Knowledge Infrastructure China Biology Medicine disc, VIP, Wanfang Database, Web of Science, PubMed, and Embase were retrieved for related randomized controlled trials published from the inception of the databases to June 3, 2023. Literature screening and data extraction were executed by 2 independent investigators. The Cochrane Collaboration tool was leveraged to appraise the quality of included studies. Meta-analysis was implemented utilizing Stata 15.
Results:
This analysis incorporated 32 studies with 2780 patients. The analysis results unveiled that compared to Western medicine treatment, modified Sijunzi Decoction significantly enhanced the clinical efficacy (relative risk [RR] = 1.241, 95% confidence interval [95% CI] = 1.199–1.285, P < .0001), lowered symptom scores (standardized mean difference [SMD] = −1.846, 95% CI = −2.160 to −1.532, P < .00001) and gastroscopic pathological scores (SMD = −1.122, 95% CI = −1.492 to −0.752, P < .00001), ameliorated quality of life (SMD = 4.294, 95% CI = 2.982–5.606, P < .00001), increased the Helicobacter pylori eradication rate (RR = 1.297, 95% CI = 1.035–1.625, P < .001), pepsinogen I levels (SMD = 2.615, 95% CI = 2.344–2.886, P < .00001), pepsinogen I/II ratio (SMD = 3.107, 95% CI = 2.811–3.403, P < .00001), and gastrin-17 levels (SMD = 1.004, 95% CI = 0.794–1.215, P < .00001), and reduced the incidence of adverse reactions (RR = 0.361, 95% CI = 0.235–0.556, P < .01) in individuals with CAG, with statistically significant discrepancies.
Conclusion:
Modified Sijunzi Decoction exhibited superior efficacy to conventional Western medicine in treating CAG. It was shown to improve the Helicobacter pylori eradication rate, reduce symptom scores, enhance quality of life, and improve pepsinogen-related indicators with a high safety profile.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference54 articles.
1. Construction and optimization of a library of Chinese medicine evidence types and their symptom entries for chronic gastritis (慢性胃炎中医证型及其症状条目库的构建和优化).;Liu;J Tradit Chin Med,2016
2. Study on the etiology and mechanism of chronic atrophic gastritis in Chinese medicine (慢性萎缩性胃炎中医病因病机研究).;Zhang;Int J Tradit Chin Med,2015
3. Clinical study on the treatment of atrophic gastritis with low-grade intraepithelial neoplasia with a formula that strengthens the spleen, benefits the stomach and removes blood stasis (健脾益胃化瘀方治疗萎缩性胃炎伴低级别上皮内瘤变的临床研究).;Zhou;J Clin Med Pract,2018
4. Effects of Yiqi and blood activation formula combined with triple therapy on inflammatory reaction and blood rheology in patients with chronic atrophic gastritis of qi deficiency and blood stasis type (益气活血方联合三联疗法对气虚血瘀型慢性萎缩性胃炎患者炎性反应和血液流变学的影响).;Wang;World Chin Med,2019
5. Consensus opinion on integrated Chinese and western medicine for the diagnosis and treatment of chronic atrophic gastritis (2017) (慢性萎缩性胃炎中西医结合诊疗共识意见 (2017)).;Chin J Integr Tradit West Med Digestion,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献